General Updates

9 July 2026 To, To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Bandra - Kurla Complex, Mumbai - 400 001 Bandra (E), Mumbai - 400 051 Scrip Code: 524669 Symbol: HESTERBIO Dear Sir: Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Sale of Equity Investment in Texas Lifesciences Private Limited Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), as amended from time to time, we wish to inform you that the Company has transferred its remaining 543,248 equity shares representing 11% of the paid-up equity share capital of Texas Lifesciences Private Limited (“TLPL”) to existing shareholders of TLPL, on 8 July 2026, in accordance with the terms approved by the Board of Directors of the Company. The transaction has been completed for an aggregate consideration of INR 23 million. Consequent upon the aforesaid transfer, the Company's shareholding in TLPL stands reduced from 11% to Nil and the Company no longer holds any equity investment in TLPL. The above information is being submitted pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. You are requested to take the above information on your record. Sincerely, For Hester Biosciences Limited Vinod Mali Company Secretary & Compliance Officer